Characteristics |
All |
Responders |
Non-responders |
p- value
|
Demography |
Demography |
Demography |
Demography |
Demography |
Sex (females, %) |
14/21 (66.7%) |
6/10 (60%) |
4/11 (36.4%) |
NS |
Age (yrs., ± SD) |
46.3 (9.7) |
39.1 (8.10) |
51.36 (8.13) |
0.003 |
Disease duration (yrs., ± SD) |
9.1 (7.49) |
7.4 (8.13) |
10.8 (6.78) |
NS |
Disease Characteristics |
Disease Characteristics |
Disease
Characteristics |
Disease Characteristics |
Disease
Characteristics |
Non-infectious complications (no. of pts., %) |
16/21 (76.2%) |
7/10
(70%) |
9/11 (81.8%) |
NS |
Baseline immunosuppression (no. of pts., %) |
3/21 (14.3%) |
1/10
(10%) |
2/11 (18.2%) |
NS |
Previous immunosuppression (no. of pts., %) |
2/21 (9.5%) |
0/10 (0%) |
2/11 (18.2%) |
NS |
Treatment Characteristics |
Treatment Characteristics |
Treatment Characteristics |
Treatment
Characteristics |
Treatment Characteristics |
IRT dose (mg/kg/month, ± SD) |
288 (69.6) |
262 (60.52) |
310.9 (71.62) |
NS |
Serum IgG (trough g/L, ± SD) |
6.13 (1.59) |
6.28 (1.94) |
6.0 (1.27) |
NS |
ATB prophylaxis (no. of pts., %) |
3/21 (14.3%) |
1/10 (10%) |
2/11
(18.2%) |
NS |
Laboratory Parameters |
Laboratory Parameters |
Laboratory Parameters |
Laboratory Parameters |
Laboratory Parameters |
Serum IgA (g/L, ± SD) |
0.1 (0.09) |
0.13 (0.13) |
0.08 (0.03) |
NS |
Serum IgM (g/L, ± SD) |
0.19 (0.18) |
0.29 (0.21) |
0.1 (0.06) |
0.002 |
Lymphocytes (E9/L, ± SD) |
1.49 (0.7) |
1.52 (0.52) |
1.42 (0.85) |
NS |
CD4+ (% of CD3+ cells, ± SD) |
57.69 (7.38) |
59.20 (5.36) |
56.75
(8.62) |
NS |
CD4+ naїve (% of CD4+ cells, ± SD) |
15.51 (13.3) |
22.44 (16.24) |
11.18 (9.89) |
NS |
CD4+ TREG (% of CD4+ cells, ± SD) |
12.27 (5.54) |
15.04 (6.28) |
10.54
(4.6) |
NS |
CD8+ (% of CD3+ cells, ± SD) |
38.46 (8.17) |
36.40 (6.07) |
39.75
(9.41) |
NS |
CD8+ naїve (% of CD8+ cells, ± SD) |
23.47 (9.58) |
26.0 (7.42) |
21.89
(10.88) |
NS |
CD8+ senescent (% of CD8+ cells, ± SD) |
49.23 (16.44) |
41.0 (18.75) |
54.38 (13.56) |
NS |
CD19+ (% of lymphocytes, ± SD) |
11.19 (6.79) |
8.52 (3.06) |
12.86
(8.09) |
NS |
CD19+ transitional (% of CD19 cells, ± SD) |
7.48 (15.94) |
2.34 (1.42) |
10.7 (20.10) |
NS |
CD19+ naїve (% of CD19+ cells, ± SD) |
68.46 (22.86) |
56.0 (18.41) |
76.25 (22.84) |
NS |
CD19+ CS (% of CD19+ cells, ± SD) |
5.0 (3.2) |
7.58 (3.09) |
3.39
(2.09) |
0.009 |
CD19+ CD21low (% of CD19 cells, ± SD) |
15.0 (21.16) |
11.64 (6.99) |
17.1 (26.96) |
NS |
T-Cell Response |
T-Cell Response |
T-Cell
Response |
T-Cell Response |
T-Cell
Response |
Cellular response at month 1 (no. of pts., %) |
5/13 (38.5%) |
3/8
(37.5%) |
2/5 (40%) |
NS |
Cellular response at month 6 (no. of pts., %) |
8/12 (66.7%) |
5/7
(80%) |
3/5 (60%) |
NS |